Allena Pharmaceuticals : Corporate Presentation July 2021

Corporate Presentation

July 2021

Allena Pharmaceuticals, Inc.

These slides, and the accompanying presentation, contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward-looking statements. All forward-looking statements are based on estimates and assumptions by our management that, although we believe them to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, including those risks and uncertainties that are described under the heading "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

This presentation also contains estimates and other statistical data made by independent parties and us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

2

Allena Pharmaceuticals: Our Mission

Developing Novel, Oral, Enzyme-Based Therapies

to Meet the Needs of Patients with Rare and Serious Kidney and Metabolic Disorders

3

Investment Highlights

• Proprietary, enzyme-based technology platform with broad applications
• Therapeutic focus on serious kidney and metabolic disorders with high unmet need
• De-riskedpivotal Phase 3 clinical program for lead product candidate reloxaliase in enteric hyperoxaluria

• Clear MoA and consistent evidence of activity and tolerability across multiple trials including first phase 3 URIROX-1 study

-URIROX-2 shares same primary endpoint and patient population as URIROX-1

• • FDA alignment on accelerated approval strategy
• Second product candidate ALLN-346 targets a high unmet need within $1B+ U.S. gout market
• • Phase 2 clinical studies to be initiated; well-tolerated in phase 1 program
• Broad patent protection for both programs
• Worldwide commercial rights for all programs
• Management team with substantial experience in developing and commercializing pharmaceutical

products for metabolic and kidney disorders

4

Leadership in Oral Enzyme Technology for Metabolic and Kidney Disorders

Formulation	Oral	Non-	GI Mechanism
Technology	Enzymes	Absorbed	of Action

Reloxaliase

ALLN-346

Enhanced stability	Therapeutic	Reduces	Leverage
in the GI tract and	candidates that	potential for	GI tract as
proprietary CMC	degrade a specific	adverse events	"auxiliary kidney"
approach	metabolite

5